Moderna Stock: Buy, Sell, or Hold?

Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna (MRNA -3.64%). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue and no commercially available products.What followed was a wild ride in which Moderna burst into the public consciousness as it developed and began selling one of the COVID-19 vaccines, putting the company and its mRNA technology at the forefront of investors' minds. Nearly four years later, the company is in a curi ...